{"nctId":"NCT01850602","briefTitle":"A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia","startDateStruct":{"date":"2013-04-23","type":"ACTUAL"},"conditions":["Hemodialysis","Hyperphosphatemia"],"count":213,"armGroups":[{"label":"PA21","type":"EXPERIMENTAL","interventionNames":["Drug: PA21"]},{"label":"Sevelamer hydrochloride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sevelamer hydrochloride"]}],"interventions":[{"name":"PA21","otherNames":[]},{"name":"Sevelamer hydrochloride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients age 20 or older, regardless of gender.\n* Receiving stable maintenance hemodialysis 3 times a week.\n* Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.\n\nExclusion Criteria:\n\n* Patients having history of a pronounced brain / cardiovascular disorder.\n* Patients having severe gastrointestinal disorders.\n* Patients having severe hepatic disorders.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment","description":"Covariate: Serum phosphorus concentrations at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.01","spread":"1.01"},{"groupId":"OG001","value":"5.33","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.14","spread":"0.68"},{"groupId":"OG001","value":"8.91","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203.6","spread":"117.1"},{"groupId":"OG001","value":"253.1","spread":"168.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":108},"commonTop":["Nasopharyngitis","Diarrhoea","Constipation"]}}}